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Abstract
Background and objectives: Efficiency-based healthcare de-
cision-making has been widely accepted for some time, with
cost per quality-adjusted life year (QALY) as the main outco-
me measure. Nevertheless, for numerous medical procedu-
res, little data are available on the cost per QALY gained. The
aim of the present study was to calculate the cost per QALY
gained with primary hip and knee replacement and to com-
pare the result with the cost per QALY for other medical pro-
cedures, as well as with the maximum threshold cost consi-
dered acceptable in Spain.
Methods: We performed a prospective cohort pre-test/post-
test study of patients undergoing primary hip or knee arthro-
plasty. Age, sex, and clinical variables were recorded. Func-
tional status and quality of life were measured by means of
the WOMAC and EuroQol instruments, respectively, before the
intervention and 6 months later. The direct costs of the inter-
vention were calculated, with length of hospital stay and the
prosthesis as the main cost drivers.
Results: A total of 80 patients, 40 from each intervention, were
included in this study. Both functional and perceived health sta-
tus improved after the intervention. The number of QALYs gai-
ned in the knee cohort was 4.64, while that in the hip cohort
was 0.86. The total cost of knee replacement was lower
(6,865.52 €) than that of hip replacement (7,891.21 €). The
cost per QALY gained was 1,275.84 € and 7,936.12 € for knee
and hip interventions, respectively. The calculations performed
included a 6% discount rate for health outcomes, a 3% infla-
tion rate for costs, and a success rate of 95% at 15 years. 
Conclusions: The costs of both knee and hip replacement
were lower than the threshold of 30,000 € per QALY consi-
dered acceptable in Spain, and compared favorably with other
medical and surgical procedures.
Key words: Cost-utility analysis. Hip arthroplasty. Knee
arthroplasty. Quality of life.
Resumen
Fundamento y objetivos: Está ampliamente aceptada la toma
de decisiones sanitarias basada en la eficiencia, con el coste
por año de vida ajustado por la calidad (AVAC) como medi-
da de resultado. No obstante, aún es escasa la disponibili-
dad de datos de coste por AVAC de las intervenciones. El ob-
jetivo de este trabajo es calcular el coste por AVAC ganado
en artroplastia de cadera y rodilla, y compararlo con los cos-
tes por AVAC de otras intervenciones, así como con el um-
bral máximo establecido. 
Métodos: Estudio de cohortes prospectivo pre-test post-test
de pacientes intervenidos de prótesis primaria de cadera o
rodilla. Se recogieron variables demográficas, clínicas, fun-
cionales y del estado de salud percibida antes de la intervención
y 6 meses después de ésta, mediante los cuestionarios
WOMAC y EuroQol, respectivamente. Se calcularon los cos-
tes directos de la intervención, considerando la prótesis y la
duración de la estancia como determinantes principales del
gasto. 
Resultados: Se incluyeron 80 pacientes, 40 por cada arti-
culación. El estado funcional y la salud autopercibida mejora-
ron tras la intervención. Se ganaron 4,64 y 0,86 AVAC en in-
tervenciones de rodilla y cadera, respectivamente. El coste por
proceso de prótesis de rodilla fue de 6.865,52 € y de cadera
de 7.891,21 €. El coste por AVAC ganado es de 1.275,84 €
y 7.936,12 € para las intervenciones de rodilla y cadera, res-
pectivamente. Se ha tenido en cuenta una tasa de descuen-
to para los resultados en salud del 6%, una inflación del 3%
y una tasa de éxito de las intervenciones del 95% a 15 años.
Conclusiones: El coste por AVAC ganado tras artroplastia
de rodilla y cadera está dentro del límite considerado acep-
table en España (30.000 € por AVAC) y resulta bien posicio-
nado en comparación con otras intervenciones. 
Palabras clave: Análisis coste-utilidad. Artroplastia de cadera.
Artroplastia de rodilla. Calidad de vida.
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Introduction
During the last 3 decades, total hip and knee re-placement (arthroplasty) have become verycommon throughout the world, and are pro-cedures that present low mortality rates. This
type of surgery is considered an effective treatment, even
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one of the most successful surgical treatments. In fact,
it is generally accepted that in these processes func-
tional benefits outweigh clinical risks and costs. However,
since this is a major surgical procedure, its application
is generally restricted to patients who, while showing dif-
ferent pathologies, suffer severe pain and functional di-
sability, as well as in cases where other treatments have
already failed.
The objective of these medical interventions is to im-
prove the condition of functional disabilities and relie-
ve pain caused by the deterioration of joints. A further
aim is to restore the necessary mobility for patients, so
they are able to maintain their functional independen-
ce and appropriate performance of daily-living activities,
thereby improving their quality of life.
The efficacy of hip and knee arthroplasty has been
assessed from several points of view. The most widely
extended analysis, from a clinical perspective, has in-
dicated that arthroplasty of both hip1-3 and knee4,5 are
effective procedures in lessening pain and improving
functionality of joints. More recently a new assessment
perspective based on related health quality of life is be-
coming widespread, which reports good results as well6,7.
Various studies in different health contexts have con-
sistently shown that the cost-effectiveness of both knee
and hip prosthetic surgery is comparable to that of other
medical and surgical interventions commonly imple-
mented, e.g. bypass surgery and renal dialysis8-10.
During the last 15 years, the number of published
investigations on economic evaluation of arthroplasties,
mainly those performed as cost-effectiveness analyses
(CEA), has noticeably increased10. Nevertheless, since
the typical measurements of outcomes in CEA usually
have a limited scope11 that is different for each type of
intervention evaluated, the results of cost-effectiveness
analysis, when used as an instrument for decision-ma-
king of healthcare resources allocation, present certain
limitations.
In the current scenario with increasing pressures re-
garding healthcare costs, decision-making about health-
care resources allocation based on explicit and objec-
tive criteria has become critically important.
In accordance with previous statements, methodo-
logical guidelines for performance of pharmacoecono-
mic evaluations, aligned with the well-known information
necessities of decision-makers, show preferences more
and more oriented towards the realisation of cost-utility
assessments12,13. Nonetheless, this technique has been,
up to now, the least applied and published technique of
economic assessments in Spain and at the internatio-
nal level as well. Although the absolute number of stu-
dies using this approach has risen, the relative share of
economic evaluations using QALYs or life-years gained
fell from 1986 to 199614. Consequently, at present, the
availability of cost-effectiveness data expressed in terms
of quality adjusted life years (QALY) is still scarce. 
The objective of this paper is to estimate the cost-
utility of primary hip and knee arthroplasty and to as-
sess its monetary value with general criteria of accep-
tability indicating an efficient cost-utility relationship. 
Methods
Design
This is a partially stochastic cost-outcome descrip-
tion, where effectiveness data were collected by means
of a prospective cohort study of patients undergoing pri-
mary, total or partial, hip or knee arthroplasty, and costs
data are deterministic. 
Patients and methods
A sample of 80 patients was selected by a stratified
random sampling method, 40 patients of each inter-
vention under study, at the University Hospital Virgen
de las Nieves of Granada during the year 2005. Patients
were selected from the waiting list for primary hip and
knee replacement surgery. Exclusion criteria were re-
vision surgery, emergencies, as well as patients lacking
mental capability to give informed consent for the sur-
gical intervention or to participate in the study plus also
lacking relatives to give such legal consent. Before ad-
mission to the hospital for the intervention, selected pa-
tients were seen in consultations in which they were in-
formed about the project and the procedures included
in it. Informed consent by the patients for voluntary par-
ticipation in the study was requested.
Sociodemographic (age, sex), clinical and some he-
althcare characteristics (duration of stay, diagnosis in-
dicating arthroplasty according to the International
Classification of Diseases, IDC-9, and medical processes
carried out) were obtained from hospital records (clini-
cal and administrative).
Functional status related to the joints under study
was assessed. We measured specific characteristics of
the joint operated on (pain, disability and stiffness of joint)
by means of the WOMAC Index, the most commonly
used tool for assessing the osteoarticular health rela-
ted quality of life, especially in reference to patients with
hip or knee arthrosis.
Health related quality of life was analysed with the
Medical Outcomes Study 36-item Short-Form Health
Survey (SF-36). 
Finally, QALYs gained were estimated by using the
EuroQol instrument. In this study we used the social Spa-
nish Euroqol tariff associated with the time trade-off
(TTO) method15,16.
In accordance with surgeons’ practice, patients were
called again for consultations six months after surgery.
We took advantage of these ordinary revisions to re-
assess functional and health related quality of life sta-
tus by using the same questionnaires.
The final impact of the intervention was assessed
as pre-test and post-test changes in the specific varia-
bles under study and by means of QALYs gained after
interventions. 
Costs were analysed from the perspective of the hos-
pital. Thus we have considered the hospital’s direct costs
incurred from interventions for hip and knee arthroplasties
(stays, prostheses, drugs).
Costs data source was the hospital’s Analytical Ac-
counting System. In order to calculate the cost per pa-
tient, we considered the 2 main short-term cost drivers
in hip and knee arthroplasties: stays and prostheses
(table 1). Costs of prosthesis are very similar between
hip and knee patients groups, but stays show high va-
riability. Then, we calculated the average cost of each
procedure considering the average stay, and a range
of maximum and minimum cost with regard to the hig-
hest and lowest in stays. 
Data analysis
A standard statistical analysis was carried out, by
means of both univariate (descriptive analysis of va-
riables) and bivariate (analysis of statistical significant
differences between pre-test and post-test scores in the
evaluated characteristics) analysis. The statistical sig-
nificance level was 1% in all cases. Analyses were per-
formed using the statistical software SPSS 12. 
In addition to the statistical significance, we evaluated
the changes in scale scores estimating the «effect size».
The effect size standardises the measurement units so
that all the various changes observed can be compa-
red17. By using the effect size measurement it is pos-
sible to know not only whether an experiment has a sta-
tistically significant effect, but also the size of any
observed effects. Within the context of a pre-test and
post-test study, effect size (hypothetical effect sizes for
the population) was calculated as the absolute value of
the mean difference divided by the standard deviation
of the differences. In this framework, .2, .5, and .8 are
small, medium, and large effect sizes, respectively18.
Cost-utility analysis
Cost-utility ratios were calculated for knee and hip
replacement. Since this is a cost-outcome description
of hip and knee replacements, there is no comparati-
ve analysis, so incremental cost-utility ratios have not
been calculated. 
It must be pointed out that this work is not an eco-
nomic evaluation, as it does not fulfil one of the defining
characteristics of such studies: i.e. to have an implicit elec-
tion11. Actually, this paper offers a description of the cost-
outcome of 2 health interventions in an independent way.
Although we compare their results in terms of cost-ef-
fectiveness ratios (CER), we are not performing an in-
cremental analysis between both interventions, nor is an
incremental cost-effectiveness ratio (ICER) calculated.
Discount
Since the scope of the results is considered from the
moment of the replacement to 15 years later, discount
rates were applied for both costs and effectiveness. Fo-
llowing the recommendations of the working group for
standardisation of economic evaluations of health tech-
nologies in Spain19, a 6% discount rate for effectiveness
and costs has been utilised. Also a 3% annual inflation
rate was applied in estimating future costs. 
Sensitivity analysis
We performed a two-dimensional deterministic sen-
sitivity analysis by considering the worst (lowest effec-
tiveness and highest costs) and the best (highest ef-
fectiveness and lowest costs) scenarios.
Results
Forty patients who received surgery for knee arth-
roplasty, as well as 40 patients for hip arthroplasty, were
included in the study. 
Demographic and clinical characteristics show sta-
tistically significant differences between hip and knee
groups in relation to age, sex, stays and diagnosis. Re-
garding afflictions in other joints and previous surgery
of other joints, there are no such differences (table 2).
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Table 1. Unit costs of hip and knee arthroplasties
Traumatology service Knee Hip
Hospitalization total cost 14,014.415
Prosthesis total cost 1,262.868
Stays 25,566
Cost per staya 498.77
Average stay 10.27 9.33 11.21
Prosthesis unit cost 2,256 2,212 2,300
Unit cost of process 7,378.37 6,865.52 7,891.21
aWithout prosthesis.
The WOMAC Index of arthrosis in knee patients re-
ported a statistically significant functional improvement
after intervention. Taking each of the 3 dimensions of
the WOMAC Index separately, statistically significant im-
provements in all of them were found, except in the area
of stiffness. The SF-36 questionnaire reveals improve-
ments in both physical and mental dimensions, statis-
tically significant only in the former. Regarding the ef-
fect size, changes in WOMAC are «high» or «medium»
in all cases. Changes in SF-36 are «medium» for the
2 aspects considered, although much higher for the phy-
sical than for the psychological dimension (table 3).
Similar results were obtained for the hip cohort, alt-
hough in this case improvements were generally more
moderate. The WOMAC Index for this group shows dif-
ferences not considered statistically significant. Re-
garding the three WOMAC dimensions, as in the case
of the knee cohort, statistically significant improvements
were found for pain and disability, while the improvement
in stiffness of joints was not statistically significant. Again,
as with the knee cohort, in the assessment of the he-
alth related quality of life, a statistically significant im-
provement was reported in the physical dimension. For
the mental aspect, a mild decrease, while not statisti-
cally significant, was observed. The effect size in the
WOMAC questionnaire ranked «high» in all cases, for
dimensions and total score as well. The SF-36 showed
a «medium» change in the physical aspect and a «small»
one in the psychological dimension (table 3).
Costs of interventions are calculated considering the
two main determinants of arthroplasties: stays and prost-
hesis. Knee arthroplasty costs 6,865.52 € (range,
6,426.60-7,309.43) while the total cost of hip arthroplasty
is 7,891.21 € (range, 7,407.40-8,380.00) (table 1).
Assuming a survival rate of the prosthesis of 15 years
in 95% of the cases20, the total gains of QALYs were
4.64 (95% CI, 2.23-6.72) in the knee cohort and 0.86
(95% CI, 0.15-1.51) in the hip cohort, both statistically
significant (p < 0.05) (table 4). 
Regarding the number of QALYs gained and the dis-
counted total costs for each intervention, the cost per
QALY gained in knee arthroplasties is 1,275.84 €, and
the cost per QALY gained in hip arthroplasty is 7,936.12
€ (table 4). 
Sensitivity analysis shows that changes in the ef-
fectiveness and costs considered have an important ef-
fect on the cost-utility ratio for each intervention. In the
case of knee arthroplasty, the cost per QALY in the worst
scenario is more than twice the baseline cost-utility ratio,
and the cost per QALY in the best scenario is almost
half of the baseline. This situation is more evident in hip
arthroplasties, where the worst scenario is six times the
baseline cost-utility and the best scenario is almost half
of the baseline value (table 4). 
Discussion
Total hip and knee arthroplasty are not new surgi-
cal procedures, but their widespread application is re-
latively recent. In the last decades both indications and
effective age range were extended, with a reduced or
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Table 2. Characteristics of patients who underwent hip and
knee arthroplasty
Variable
Knee (n = 40) Hip (n = 40)
pa
Mean SD Mean SD
Age 71.70 7.76 63.20 12.03 p < 0.01
Stays 9.33 8.95 11.21 9.03 p < 0.01
n = 40 Percentage n = 40 Percentage pb
Sex p < 0.01
Female 31 77.50 24 60.00
Male 9 22.50 16 40.00
Diagnosis p < 0.01
Located osteoarthrosis 31 77.50 16 40.00
Closed femur neck fracture 0 0.00 10 25.00
Others 9 22.50 14 35.00
Other joints affected (No) 34 85.00 39 97.50 0.28
Previous surgery of other joints (No) 30 75.00 35 87.50 0.28
aTest t-Student.
bTest chi square.
SD: standard deviation.
7Table 3. Functional and health status
Variable
Preoperative Postoperative
pa Effect
Mean SD Mean SD
Size
Knee (n = 40)
WOMAC Pain 9.45 3.47 3.00 4.03 < 0.05 1.68
Stiffness 3.75 1.77 3.55 2.14 0.727 0.74
Functional capability 37.15 14.28 24.20 12.58 < 0.05 1.03
Total score 50.35 17.79 30.75 17.12 < 0.05 1.18
SF 36 Physical D 31.57 7.01 37.13 9.32 < 0.05 0.79
Mental D 46.08 13.75 49.78 12.66 0.161 0.27
Hip (n = 40)
WOMAC Pain 9.36 2.73 4.50 4.50 < 0.05 1.61
Stiffness 4.72 1.35 3.70 2.10 0.142 1.62
Functional capability 40.45 7.60 24.22 19.96 < 0.05 1.49
Total score 54.54 8.73 32.50 22.54 0.718 1.79
SF 36 Physical D 32.76 10.05 36.10 10.64 < 0.05 0.33
Mental D 46.72 14.40 45.81 16.33 0.105 0.06
SD: standard deviation.
aTest t-Student.
null mortality rate and good clinical outcomes. The re-
sults realised in this work describe positive outcomes
for both interventions, from an objective clinical point of
view as well as from the health perceived quality of life
expressed by the patients. In other words, the two pers-
pectives were similar, although those aspects did not
always converge21. These results bear out those obtained
in previous studies6,22-24. Nevertheless, due to the va-
riety of instruments used and the different periods of time
under study in each investigation, the results can hardly
be considered comparable regarding effect size. At any
rate, the effect size measurement allows us to obser-
ve the direction of certain trends. 
Cost-utility analysis, although regarded as the most
suitable economic evaluation method for healthcare re-
sources allocation, still represents a very small per-
centage of the economic evaluation published in he-
althcare technologies in general and in particular in the
field of orthopaedic surgery. Reviews including econo-
mic evaluations of both knee and hip arthroplasty co-
rroborate this observation. Thus, a review of economic
evaluations of knee arthroplasty published between 1966
and 1996 found that only 2.5% of the reviewed papers
were cost utility analyses, the majority being cost-mi-
nimisation analyses25. On the other hand, reviews in-
cluding economic evaluations of hip arthroplasty carried
out between 1966-199626 and 1966-200210 as well, found
that 5.88% of the former and 16% of the latter were cost-
utility analyses, the majority being cost-effectiveness
analyses. Furthermore, even though the developers of
the EuroQol recommend it as a complementary ins-
trument27, there are only a few studies on the outcome
of arthroplasty in which the EuroQol was employed28.
Direct costs and cost per QALY of hip and knee arthro-
plasties are lower than previously reported costs esti-
mated for other countries9. But our present costs, com-
pared with results of a prior Spanish study, in the case
of total hip arthroplasty are higher than before24. This dif-
ference is mainly due more to the difference in QALYs
gained between both studies (45% higher in the former)
than to the difference in costs (16% higher in our study),
although differences in the periods of time considered
make direct comparisons of outcomes inadvisable.
A great difference of cost per QALY gained is ob-
served between hip and knee interventions. As in other
studies6, patients suffering knee dysfunctions report
worse pre-operative results in quality of life than patients
with hip dysfunctions, but 6 months later, knee patients
report better results than do patients of hip surgery. Be-
sides the higher cost per process of hip arthroplasty,
we obtained a more favourable cost per QALY rela-
tionship for knee arthroplasties than for hip. This result
is the opposite of that obtained by Rässänen et al (2007),
where total hip arthroplasty emerged as more cost-ef-
fective than total knee arthroplasty with a cost per QALY
of 4,517 and 9,421 €, respectively29. Alternatively, Chang,
Pellissier, and Hazen (1996) report a cost per QALY of
4,637 €30 and Segal et al (2004) suggest a cost per
QALY of 3,639 € for knee replacement31. In all the pre-
vious analyses, the time horizon considered up to the
post-test assessment was 1 year, against 6 months con-
sidered in the present work. This is the main metho-
dological difference that we have found between our
study and those previously published. In our opinion this
circumstance could explain the higher cost per QALY
calculated for hip arthroplasty.
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7Table 4. Costs per QALY gained of hip and knee arthroplasties and sensitivity analysis
Joint Scenario Stays Social Tariff Euroqol QALYs Cost Cost 
Preoperative Postoperative gaineda per process (€)b per QALY
Knee
Average 9.33 0.20 0.64 4.64 5.921,71 1.275,84
Best 8.44 6.72 5.543,13 824,87
Worst 10.21 2.23 6.304,59 2.827,17
SD 0.35 0.26
Hip
Average 11.21 0.47 0.55 0.86 6.806,40 7.936,12
Best 10.24 1.51 6.389,10 4.231,19
Worst 12.19 0.15 7.228,00 48.186,64
SD 0.35 0.32
SD: standard deviation.
aQALYs gained assuming a survival rate of the prosthesis of 15 years in 95% of the cases and a 6% discount rate: ( ) 95%
bTotal cost assuming an inflation rate of 3%: ( )Cost/n(1 + i)n
15
Σ
n = 0
QALYs gained
(1 + r)n
15
Σ
n = 0
From an extended point of view, comparing the analy-
sed interventions with «doing nothing» (zero outcomes
and costs), we can consider the cost-effectiveness ra-
tios as incremental cost effectiveness ratios (ICER). With
this assumption, the processes under investigation are
well positioned in cost-utility acceptability values re-
garding the generally accepted cost-effectiveness th-
reshold (30,000 € per QALY gained in Spain32 and
around 50,000 € per QALY gained accepted in other
contexts33,34). If we take as comparative environment
other technologies considered to be cost-effectives in
Spain as point of reference, the range of acceptability
is between 57.76 € and 6,783.07 €32 (2007 euros) and
thus knee arthroplasty can be considered cost-effecti-
ve whereas hip arthroplasty exceeds this range. The sen-
sitivity analysis on extreme scenarios shows that, in the
worst possible case, the cost-utility ratio for hip arthro-
plasties would exceed the Spanish efficiency threshold,
but remain within the boundaries of international ac-
ceptability. From the global perspective, the cost-utility
ratios published from 1976 to 200135 in general report
higher cost per QALY gained than the ones obtained
in our study for several diseases (table 5). 
Previous results should be considered with certain
limitations taken into account. First of all, the small sam-
ple size together with the analysis of only one hospital
greatly reduce the possibility of generalising the results
obtained. Secondly, we do not consider the long term
costs of hip and knee arthroplasties, e.g. revision sur-
gery costs. This fact can lead to an undervaluation of
cost per QALY gained with the analysed interventions. 
It is worth mentioning that comparison by means of
league tables, at national and international levels, has
a limited scope when the structure of costs is not known.
Still, in order to facilitate comparisons between cross-
national and cross-care interventions, we do agree with
the advice of guidelines encouraging researchers to re-
port the results of economic evaluations of healthcare
technologies in QALYs.
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